Home » Newsletters » BioWorld Science

BioWorld Science

April 8, 2015

View Archived Issues

Constellation Pharmaceuticals tests EZH2 inhibitor in patients with B-cell lymphoma

German scientists report development of bi- or multispecific antibodies

rHuCat-L shows promising results for the treatment of cellulite

State University of New York patents novel dendrimer-drug conjugates

Ocular Therapeutix reports results from second phase III trial of dexamethasone punctal plug

New OX2R antagonist shows potential for the treatment of insomnia

sGC activators prevent progression of diabetic nephropathy

Nabriva Therapeutics raises funds to advance new class of antibiotic

Repros' enclomiphene eligible for new active substance status

PCI Biotech begins preclinical research collaboration in siRNA therapeutics

Scripps receives grant to develop treatments for intellectual disability, autism, epilepsy

BIND Therapeutics extends global collaboration with Pfizer to develop multiple Accurins

Carna Biosciences patents novel BTK inhibitors

Karyopharm Therapeutics discloses PAK inhibitors

Alios BioPharma develops new antivirals

GlaxoSmithKline describes novel inhibitors of RIP-1 and RIP-2 kinases

Targeting IRS proteins presented as a new approach for prostate cancer therapy

Sanofi Pasteur to use VBI Vaccines' lipid particle vaccine technology

GlaxoSmithKline's SARM for muscle wasting diseases

Gilead Sciences files NDA for emtricitabine/tenofovir alafenamide combination for HIV infection

Analysis of HLA genes links genotypes to risk of atherosclerosis in patients with psoriasis

TaxusCardium licenses ASEAN and Latin American rights to Generx to Dr Reddy's

Celtaxsys to start phase II trial of oral CTX-4430 in acne vulgaris

AmorChem invests in Canada's Personalized Cancer Immunotherapy Program

Cytori Therapeutics' ECCS-50 receives E.U. orphan drug designation for scleroderma

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 5, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...